Global Post-Market Clinical Follow-up of the Treovance Stent-Graft for Endovascular Aneurysm Repair: One-Year Results From the RATIONALE Registry

Raman Uberoi, Carlo Setacci, Mario Lescan*, Antonio Lorido, David Murray, Zoltán Szeberin, Tomasz Zubilewicz, Vincent Riambau, Angsu Chartrungsan, Jörg Tessarek, Marek Iłżecki, Hartmuth Gortz, Matthias Thenholt, Maher Fattoum, Semih Buz, Piergiorgio Cao, Domenico Benevento, Giancarlo Palasciano, Feras Abdallah, John BoyleS. Llagostera Pujol, Carlos Esteban, Nilo Mosquera, Enrique Aracil Sanus, Ignacio Iglesias Negreira, J. T.F.J. Raymakers, Joost van Herwaarden, Georgios Pitoulias, Theodoros Kratimenos, Carl Magnus Wahlgren, Claes Forssell, Greg Fulton, Lars Lonn, Gustav Pedersen, Jorge Vergara, Manuel Espindola Silva, Stephen Wing Keung Cheng, Phan Minh Anh, Carlos David Calderas, Patrick Bohan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

Purpose: To evaluate the safety and performance of the Treovance stent-graft. Methods: The global, multicenter RATIONALE registry (ClinicalTrials.gov; identifier NCT03449875) prospectively enrolled 202 patients (mean age 73.0±7.8 years; 187 men) with abdominal aortic aneurysms (AAA) suitable for endovascular aneurysm repair (EVAR) using the Treovance. The composite primary safety endpoint was site-reported all-cause mortality and major morbidity. The primary efficacy outcome was clinical success. Further outcomes evaluated included technical success; stent-graft migration, patency, and integrity; endoleak; and aneurysm size changes. Results: Technical success was 96% (194/202); 8 patients had unresolved type I endoleaks at the end of the procedure. There was no 30-day mortality and 1% major morbidity (1 myocardial infarction and 1 bowel ischemia). Clinical success at 1 year was confirmed in 194 (96%) patients; 6 of 8 patients had new/persistent endoleaks and 2 had aneurysm expansion without identified endoleak. A total of 8 (4%) reinterventions were required during the mean 13.7±3.1 months of follow-up (median 12.8). At 1 year, the Kaplan-Meier estimate for freedom from reintervention was 95.6% (95% CI 91.4% to 97.8%). Other estimates were 95.5% (95% CI 91.7% to 97.6%) for freedom from endoleak type I/III and 97.4% (95% CI 94.2% to 98.9%) for freedom from aneurysm expansion. Thirteen (6.4%) patients died; no death was aneurysm related. Conclusion: The RATIONALE registry showed favorable safety and clinical performance of the Treovance stent-graft for the treatment of infrarenal AAAs in a real-world setting.

Original languageEnglish
Pages (from-to)726-734
Number of pages9
JournalJournal of Endovascular Therapy
Volume25
Issue number6
DOIs
Publication statusPublished - 1 Dec 2018

Keywords

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Aortic Aneurysm, Abdominal/diagnostic imaging
  • Blood Vessel Prosthesis
  • Blood Vessel Prosthesis Implantation/adverse effects
  • Endovascular Procedures/adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications/mortality
  • Product Surveillance, Postmarketing
  • Prospective Studies
  • Prosthesis Design
  • Registries
  • Risk Assessment
  • Risk Factors
  • Stents
  • Time Factors
  • Treatment Outcome
  • Young Adult
  • stent-graft
  • endograft
  • abdominal aortic aneurysm
  • endoleak
  • registry
  • reintervention
  • endovascular aneurysm repair
  • occlusion
  • mortality

Fingerprint

Dive into the research topics of 'Global Post-Market Clinical Follow-up of the Treovance Stent-Graft for Endovascular Aneurysm Repair: One-Year Results From the RATIONALE Registry'. Together they form a unique fingerprint.

Cite this